Al Borg Laboratory Home About Us Contact Us
Arabic Version
About Al Borg Labs
Branches
Organogram
Staff
Equipment
Bar Code
Test Menu
Patient Results
Jobs
Training Courses
Health Tips
Newsletters
Related Links
Contact Us
Arabic Version

Al Borg Technical Newsletters
HEPATITIS C : UPDATE 12/06/2003

Hepatitis C update

HCV- RNA by branched DNA and PCR
 
       Due to the daily fluctuations in the viral load, recent studies have shown that success of antiviral
       therapy depends on the viral load estimation by branched DNA. Quantitation should be performed
       before starting therapy then at  three and twelve months during therapy in order to modify therapy
       accordingly. Treatment is considered successful if  HCV-RNA by branched DNA is below 
       < 3,200 copy / ml and HCV-RNA by PCR is negative. However; complete success of therapy cannot
       be guaranteed unless HCV positive strands in mononuclear cells & HCV in liver biopsy are also negative.
  
   
       Branched DNA is a reliable standardized procedure that does not give false negative results.However,
       this methodology cannot diagnose a viral load below < 3,200 copy / ml. Thus branched DNA results 
       should not be reported as negative without  a negative PCR result.

        HCV-RNA by PCR on the other hand is more sensitive hence can detect a viral load 
   
    below < 3,200 copy / ml. In addition, PCR is more sensitive than branched DNA in diagnosing 
        the very early phase of HCV infection.  
                                 Both procedures are available in our lab to reach a conclusive diagnosis.

HCV positive strands in Mononuclear cells
        Organs other than the liver such as peripheral blood mononuclear cells can act as a 
        reservoir
for HCV infection. 
        Such a reservoir can be detected by the HCV positive strand test.

HCV  negative strands in Mononuclear cells
        HCV negative strands on the other hand denote HCV replication hence the need to
       
continue therapy.
HCV genotype and subtype          
        Typing of hepatitis C is clinically important because some genotypes do not respond to
        interferon therapy ; in addition typing is of  prognostic value since some genotypes develop
       
chronic hepatitis, cirrhosis and or hepatocellular carcinoma faster than others.
         Patients who have undergone liver transplantation  or are HCV positive strand should also
         be typed to point out those who may become reinfected and develop chronic liver disease or
         cirrhosis in the new graft.
HCV- RNA in liver biopsy
        Liver biopsy is essential in determining the presence of fibrosis or cirrhosis as well as the
        degree of inflammatory changes.
        There is no specific histochemical stain for hepatitis C virus,  hence the only accurate method to 
        demonstrate presence of the virus in the liver is by In Situ Hybridization (ISH).
        This test is particularly useful in patients who are seronegative yet the virus may still be present 
        and replicating in the hepatocyte.
RIBA or LIA
         To confirm the positive  HCV IgG results .

HEPATITIS C : CHOOSING THE RIGHT TEST
Diagnosis of: HCV infection
        - History of risk factors such as blood transfusion. 
        - Clinical signs & symptoms of liver disease.
        - Liver enzymes. Total bilirubin, Prothrombin time & Alkaline Phosphatases .
        - Early phase of infection : HCV-RNA by PCR + HCV IgM & IgG .
        - Ongoing infection HCV-IgG & HCV IgM + HCV-RNA  by PCR.
Therapy  :
          HCV genotype & subtype.
          HCV-RNA by branched DNA.
Successful therapy  :                   
         HCV-RNA by branched DNA : below < 3,200 copy / ml.
         HCV-RNA by PCR : negative.
         HCV positive strands : negative.
         HCV in liver biopsy by ISH : negative.

Print This Newsletter          Back to Technical Newsletters

Copyright © 2003-2004 Al Borg Laboratory. All Right Reserved